Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Clinical oncology (Royal College of Radiologists (Great Britain))
- Publicado em
- 16 nov 2023
- Citações
- 6
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
X Hong, Y Zhang, Z Chi, Q Xu, W Lin, Y Huang, T Lin, Y Zhang
Descritores MeSH
- Programmed Cell Death 1 Receptor
- Prostatic Neoplasms, Castration-Resistant
- Ligands
- Male
- Immune Checkpoint Inhibitors
- B7-H1 Antigen
- Prostate-Specific Antigen
- Humans
Veja também
Estudos relacionados
- PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials
- Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials
- Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis
- Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis
- Benefício clínico e segurança da imunoterapia combinada e terapia alvo no câncer de próstata